Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M H Silverman

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
International Journal of Clinical Pharmacology and Therapeutics|June 5, 2004
Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy menA R van Troostenburg, D Lee, T R Jones, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 21, 2011
Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trialM David, L Akerman, M Ziv, et al.
International Journal of Clinical Pharmacology and Therapeutics|November 2, 2004
Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young menA R van Troostenburg, E V Clark, W D H Carey, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 27, 2024
Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1)K A Papp, S Beyska-Rizova, M L Gantcheva, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
International Journal of Clinical Pharmacology and Therapeutics|June 5, 2004
Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy menA R van Troostenburg, D Lee, T R Jones, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 21, 2011
Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trialM David, L Akerman, M Ziv, et al.
International Journal of Clinical Pharmacology and Therapeutics|November 2, 2004
Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young menA R van Troostenburg, E V Clark, W D H Carey, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 27, 2024
Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1)K A Papp, S Beyska-Rizova, M L Gantcheva, et al.
Pageof 2